多粘菌素B血液灌流对需CRRT的脓毒症急性肾损伤患者临床效果不确定
本研究纳入231例接受CRRT的脓毒症患者,比较单用CRRT与PMX-HP联合CRRT。主要终点为28天和90天全因死亡率。尿量、呼吸机支持和SOFA评分两组无显著差异。结论:在需CRRT的脓毒症急性肾损伤患者中,额外使用PMX-HP不改善临床结局。
要点
- 在需CRRT的脓毒症急性肾损伤患者中,加用PMX-HP未改善28天和90天全因死亡率。
- 两组尿量、呼吸机支持和SOFA评分无显著差异。
- 匹配变量包括ARDS、机械通气、ECMO、腹腔感染源、年龄、正性肌力药评分、SOFA评分、CRP和降钙素原。
- 研究提示对需CRRT的脓毒症急性肾损伤患者,不应常规加用PMX-HP。
适用人群与场景
- 接受CRRT的脓毒症患者,包括单用CRRT或PMX-HP联合CRRT者。
诊断标准与关键阈值
- 脓毒症诊断标准原文未提及。
- 急性肾损伤诊断标准原文未提及。
- CRRT启动指征原文未提及。
处置流程与药物剂量
- 原文未提及PMX-HP的具体操作参数、剂量、频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性观察性研究(基于倾向评分匹配分析)。
- 人群:接受CRRT的脓毒症患者。
- 干预与对照:PMX-HP联合CRRT vs 单用CRRT。
- 主要终点:28天和90天全因死亡率;匹配后PMX-HP联合CRRT组28天和90天死亡率显著高于单用CRRT组。
- 次要终点:尿量、呼吸机支持、SOFA评分两组无显著差异。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:回顾性观察性研究,采用倾向评分匹配。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确提及;设计本身为观察性研究,存在残余混杂可能。
对床旁实践的改变
- 在需CRRT的脓毒症急性肾损伤患者中,不应常规加用PMX-HP以改善生存率。
- 原文未提及适用与不适用人群的具体标准。
- 常见陷阱:原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Polymyxin B hemoperfusion (PMX-HP) may improve the clinical outcomes of patients with sepsis and gram-negative bacteremia by reducing endotoxin levels. However, the recent studies with the variable degree of renal support have shown that the improvement of survival rate by PMX-HP remains unclear in such patients. Therefore, we investigated whether the addition of PMX-HP to continuous renal replacement therapy (CRRT) could improve the survival rate than CRRT alone. This study included 231 patients with sepsis undergoing CRRT alone or PMX-HP with CRRT. Primary outcomes were 28-day and 90-day all-cause mortality. Urine output, ventilator support, and Sequential Organ Failure Assessment (SOFA) score were not significantly different between the two groups. Crude 28-day and 90-day mortality rates were higher in the PMX-HP with CRRT group than in the CRRT-alone group. To correct for disease severity, propensity score (PS) matching was performed with acute respiratory distress syndrome, mechanical ventilation support, extracorporeal membrane oxygenation, infection source (abdomen), age, inotropic score, SOFA score, C-reactive protein, and procalcitonin levels. Sixty-six PS-matched pairs revealed significantly higher 28-day and 90-day mortality rates in the PMX-HP with CRRT group than in the CRRT-alone group. Considering the mortality rates after PS matching, the additional use of PMX-HP does not improve the clinical outcomes of patients with sepsis and acute kidney injury requiring CRRT.
参考来源
- Lee JM, Baek SD, Kim TH, et al. Uncertain Clinical Effect of Polymyxin B Hemoperfusion in Patients with Septic Acute Kidney Injury Requiring Continuous Renal Replacement Therapy. Shock. 2021. PMID: 33606479. doi:10.1097/SHK.0000000000001752
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。